E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Heterozygous familial hypercholesterolemia and Homozygous familial hypercholesterolemia |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10054380 |
E.1.2 | Term | Familial hypercholesterolemia |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10057080 |
E.1.2 | Term | Homozygous familial hypercholesterolemia |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10057079 |
E.1.2 | Term | Heterozygous familial hypercholesterolemia |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the safety and tolerability of single and multiple doses of ISIS 703802 administered subcutaneously to healthy subjects with elevated triglycerides (TG) and subjects with familial hypercholesterolemia.
• To evaluate the pharmacokinetics (PK) of single and multiple SC doses of ISIS 703802 in healthy subjects with elevated TGs and in multiple-dose subjects with familial hypercholesterolemia.
• To evaluate the effects of single and multiple SC doses of ISIS 703802 on pharmacodynamics in healthy subjects with elevated TG and in multiple-dose subjects with familial hypercholesterolemia, including: plasma angiopoietin-like 3 (ANGPTL3), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), non-high density lipoprotein cholesterol (non HDL-C), very low density lipoprotein cholesterol (VLDL-C), and TG.
• To explore the effects of multiple SC doses of ISIS 703802 on post-heparin lipoprotein lipase (LPL) and TG. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria for All Cohorts:
•Must have given written informed consent and be able to comply with all study requirements
•Males or females 18 to 65 years, inclusive, at the time of informed consent
•BMI ≤ 35.0 kg/m2
•Females must be non-pregnant and non-lactating, and either surgically sterile or postmenopausal.
•Males must be surgically sterile, abstinent or using an acceptable contraceptive method
Inclusion Criteria for Cohort EE Only:
•Homozygous FH diagnosis and fasting LDL-C ≥ 190 mg/dL (4.9 mmol/L)
Inclusion Criteria for Cohort FF Only:
•Heterozygous FH diagnosis and fasting LDL-C ≥ 160 mg/dL (4.1 mmol/L)
Inclusion Criteria for Cohorts EE and FF Only:
•Maximally tolerated stable LDL-C lowering agents (stable for at least 12 weeks)
•On stable low-fat diet
•Stable weight (± 4 kg) for ≥ 6 weeks prior to screening |
|
E.4 | Principal exclusion criteria |
Exclusion Criteria for All Cohorts:
•Known history or positive test for HIV, HCV, or HBV
•Treatment with another Study Drug, biological agent, or device within one-month or 5-half-lives of screening
•Regular use of alcohol within 6 months of screening
•Use of concomitant drugs unless authorized by the Sponsor Medical Monitor
•Known contraindication and/or allergy to heparin
•Smoking > 10 cigarettes a day
•Considered unsuitable for inclusion by the Principal Investigator
Exclusion Criteria for Cohorts EE and FF:
•Myocardial infarction, percutaneous transluminal coronary intervention, or coronary artery bypass graft surgery within 12 weeks prior to screening, or cerebrovascular accident within 24 weeks prior to screening. Subjects with adequately treated stable angina, per Investigator assessment, may be included
•Congestive heart failure defined by NYHA Classes III or IV
•T2DM with HbA1c > 8.0%
•Prior treatment with gene therapy
•Currently receiving apheresis treatments or last apheresis treatment was within 8 weeks of screening |
|
E.5 End points |
E.5.1 | Primary end point(s) |
•Safety and tolerability of single and multiple doses of IONIS ANGPTL3-LRx (incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters)
The safety and tolerability of IONIS ANGPTL3-LRx will be assessed by determining the incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters by dose. Safety results in subjects dosed with IONIS ANGPTL3-LRx will be compared with those from subjects dosed with placebo.
•Pharmacokinetics after single and multiple doses of IONIS ANGPTL3-LRx.
The plasma pharmacokinetics (concentration-time results) of IONIS ANGPTL3-LRx (unconjugated and conjugated ASO) will be assessed following single and multiple-dose SC administration. The amount of IONIS ANGPTL3-LRx excreted in urine at selected 24-hour intervals will also be determined.
•Pharmacodynamics of IONIS ANGPTL3-LRx (Changes in serum ANGPTL3 levels)
Changes in serum angiopoietin-like 3 (ANGPTL3) levels compared to baseline |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Pharmacodynamic effects of IONIS ANGPTL3-LRx:
Effects of IONIS ANGPTL3-LRx on changes in ANGPTL3 plasma protein compared to baseline. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Double blind and Open Label Cohorts |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |